Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A11602 | ISIN: NL0010832176 | Ticker-Symbol: 1AE
Tradegate
17.04.25
21:26 Uhr
524,60 Euro
+0,20
+0,04 %
1-Jahres-Chart
ARGENX SE Chart 1 Jahr
5-Tage-Chart
ARGENX SE 5-Tage-Chart
RealtimeGeldBriefZeit
522,80526,8017.04.
523,00525,6017.04.

Aktuelle News zur ARGENX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.04.FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting2
11.04.argenx SE: argenx Announces Annual General Meeting of Shareholders on May 27, 20252
11.04.Argenx stays on a roll with Vyvgart, gaining FDA nod for at-home prefilled syringe2
11.04.Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug4
11.04.FDA Approves argenx's VYVGART Hytrulo Prefilled Syringe for Self-Injection3
11.04.What 11 Analyst Ratings Have To Say About argenx7
11.04.Stifel maintains $780 target on argenx stock after FDA nod3
ARGENX Aktie jetzt für 0€ handeln
11.04.Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe3
11.04.Guggenheim maintains Buy on Argenx stock, target at $1,1003
11.04.Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket3
11.04.Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP10
10.04.argenx SE: argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy124VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection provides gMG and CIDP patients with flexibility...
► Artikel lesen
08.04.Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients4
08.04.ARGENX SE - 6-K, Report of foreign issuer2
08.04.argenx SE: argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP3
20.03.P/E Ratio Insights for argenx8
20.03.ARGENX SE - 20-F, Annual and transition report of foreign private issuers3
20.03.ARGENX SE - 6-K, Report of foreign issuer1
17.03.Bernstein double upgrades Argenx to "outperform," raises price target to €7556
17.03.Bernstein raises argenx stock rating, hikes target to EUR7553
Seite:  Weiter >>
102 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1